Role of the α1 blocker doxazosin in alcoholism: a
proof-of-concept randomized controlled trial by Kenna, George A. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Faculty Publications, Department of Psychology Psychology, Department of 
2015 
Role of the α1 blocker doxazosin in alcoholism: a proof-of-
concept randomized controlled trial 
George A. Kenna 
Carolina L. Haass-Koffler 
William H. Zywiak 
Steven M. Edwards 
Michael B. Brickley 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/psychfacpub 
 Part of the Psychology Commons 
This Article is brought to you for free and open access by the Psychology, Department of at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications, 
Department of Psychology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
George A. Kenna, Carolina L. Haass-Koffler, William H. Zywiak, Steven M. Edwards, Michael B. Brickley, 
Robert M. Swift, and Lorenzo Leggio 
Role of the α1 blocker doxazosin in alcoholism: a
proof-of-concept randomized controlled trial
George A. Kenna1, Carolina L. Haass-Koffler2,3, William H. Zywiak1,4, Steven M. Edwards5,
Michael B. Brickley2, Robert M. Swift1,6 & Lorenzo Leggio2,3
Departments of Psychiatry and Human Behavior1 and Behavioral and Social Sciences2, Center for Alcohol and Addiction Studies, Brown University, Providence,
RI, USA, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism, National Institute
on Drug Abuse, National Institutes of Health, Bethesda, MD, USA3, Decision Sciences Institute, PIRE, Pawtucket, RI, USA4, Department of Psychology, University
of Nebraska-Lincoln, Lincoln, NE, USA5 and Veterans Affairs Medical Center, Providence, RI, USA6
ABSTRACT
Evidence suggests that the norepinephrine system represents an important treatment target for alcohol dependence
(AD) and the α1-blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients. The α1-blocker
doxazosin demonstrates a more favorable pharmacokinetic profile than prazosin, but has never been studied for AD. A
double-blind placebo-controlled randomized clinical trial was conducted in AD individuals seeking outpatient treat-
ment. Doxazosin or matched placebo was titrated to 16 mg/day (or maximum tolerable dose). Drinks per week (DPW)
and heavy drinking days (HDD) per week were the primary outcomes. Family history density of alcoholism (FHDA),
severity of AD and gender were a priori moderators. Forty-one AD individuals were randomized, 30 (doxazosin = 15)
completed the treatment phase and 28 (doxazosin = 14) also completed the follow-up. There were no significant
differences between groups on DPW and HDD per week. With FHDA as a moderator, there were significant
FHDA × medication interactions for both DPW (pcorrected = 0.001, d = 1.18) and HDD (pcorrected = 0.00009, d = 1.30). Post
hoc analyses revealed that doxazosin significantly reduced alcohol drinking in AD patients with high FHDA and by
contrast increased drinking in those with low FHDA. Doxazosin may be effective selectively in AD patients with high
FHDA. This study provides preliminary evidence for personalized medicine using α1-blockade to treat AD. However,
confirmatory studies are required.
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INTRODUCTION
Alcohol dependence (AD) afflicts about 10 percent of
the US population causing serious morbidity and mor-
tality. Only a few medications are approved for AD,
however, their therapeutic effects are modest or limited
to certain subgroups (for review, see Leggio et al. 2009).
Thus, developing new medications for AD remains a
priority.
Evidence suggests an important role of the norepi-
nephrine system inAD (for review, see Koob 2008), point-
ing to the norepinephrine system as a potentially
important pharmacological target. Norepinephrine
innervateskey limbicareas forarousal, reinforcementand
stress—processes involved in developing andmaintaining
AD (Koob 2008). Elevated epinephrine (Ehrenreich et al.
1997) and norepinephrine (Patkar et al. 2004) plasma
levels have been found in abstinent alcoholic patients.
Hyperexcitability, a key feature in the predisposition and
development of AD, is associated with increased
adrenergic activation (Koob 2008). Enhanced acoustic
startle response is a proxy for hyperexcitability and brain
noradrenergic-α1 mechanisms mediate enhanced acous-
tic startle response (Stevens, McCarley & Greene 1994),
which is characteristic in alcohol-preferring (P line)
animals (Chester, Blose & Froehlich 2004) and AD
patients (Krystal et al. 1997). In animals, norepinephrine
depletion attenuates ethanol self-administration (Amit
et al. 1977) and alcohol withdrawal symptoms
(Trzaskowska et al. 1986); α1-receptor antagonism
reduces the locomotor hyperactivity produced by alcohol
withdrawal (Trzaskowska et al. 1986).
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CLINICAL STUDY
In summary, animal and human studies demonstrate
that α1-blockade may represent a therapeutic approach
for AD. Recently, promising results have been obtained
with the noradrenergic α1-blocker prazosin, approved by
the Food and Drug Administration (FDA) for hyperten-
sion and benign prostatic hyperplasia. Prazosin reduced
alcohol self-administration and was more potent in
ethanol-dependent rats than in non-dependent, suggest-
ing that prazosin blocks dependence-induced increases
in responding to alcohol (Walker et al. 2008). Subse-
quently, both acute and chronic prazosin treatment
demonstrated decreased ethanol consumption in alcohol
P rats (Rasmussen et al. 2009). Prazosin also blocked
yohimbine- and footshock-induced reinstatement of
alcohol seeking (Le et al. 2011).
Based on this pre-clinical evidence, a 6-week pilot
randomized clinical trial (RCT) was performed (Simpson
et al. 2009); 24 AD individuals were treated with placebo
or prazosin 16 mg, divided over three daily doses. During
the last 3 weeks of the study, the prazosin group, com-
pared with placebo, had a statistically significant reduc-
tion in drinking days per week and a trend in reduction in
drinks per week (DPW; Simpson et al. 2009). No signifi-
cant medication effect on craving was found. Although
frequent non-serious adverse events (AEs), such as dizzi-
ness, lack of energy, drowsiness and one case of syncope,
were reported, there were no serious AEs (Simpson et al.
2009). In a more recent study with detoxified abstinent
AD individuals (n = 17), prazosin (16 mg/day), com-
pared with placebo, decreased both stress- and cue-
induced alcohol craving measured via guided imagery
exposures to stress, alcohol cue and neutral-relaxing/
control conditions (Fox et al. 2012).
The noradrenergic α1-blocker doxazosin is also FDA-
approved for hypertension and benign prostatic hyperpla-
sia. Doxazosin and prazosin share the same piperazine
ring structure and have a non-specific action on all three
α1-subtypes, i.e.α1A,α1B andα1D (Gross, Hanft &Mehdorn
1989). However, doxazosin has a more manageable
dosing and safety profile than prazosin. Specifically,
doxazosin is long-acting [half-life (t1/2) approximately 22
hours)] and dosed only once daily, thus facilitating adher-
ence (Kirby et al. 1998). Doxazosin is also less likely to
producehypotensionbecauseof the sloweronsetof action
and long t1/2. Furthermore, unlike other α1-blockers (i.e.
prazosin), doxazosin can be taken at any time of day, with
or without food, properties that further promote patient
adherence (Kirby et al. 1998). Thus, in clinical practice,
doxazosin is often preferred to treat hypertension
or benign prostatic hyperplasia over short-acting
α1-blockers, such as prazosin (Akduman & Crawford
2001). Therefore, given its favorable pharmacokinetics, a
proof-of-conceptRCTwasconducted to test thehypothesis
that doxazosin may represent a safe and effective medica-
tion for the treatment of AD. Specifically, the primary aim
of the study was that doxazosin, compared with placebo,
may significantly reduce alcohol consumption. Second-
ary aims were that doxazosin may significantly reduce
alcohol craving, anxiety and stress levels. Finally, we
hypothesized that family history of alcoholism, severity of
AD and gender may moderate doxazosin’s response on
alcohol consumption.
METHODS AND MATERIALS
Study design
A 10-week between-subject double-blind placebo-
controlled RCT with doxazosin was conducted at the
Brown University Center for Alcohol and Addiction
Studies (ClinicalTrials.gov: NCT01437046). The Brown
University Institutional Review Board reviewed and
approved the study. Patients were individuals seeking out-
patient treatment for AD. For inclusion/exclusion crite-
ria, see Supporting Information Table S1.
Study drug
Doxazosin or matched placebo were prepared as opaque
capsules by a compounding pharmacy and inserted into
blister packs. Consistent with the recommended titration,
doxazosin was titrated up to 16 mg daily (or maximum
tolerable dose) during the first 4 weeks (Supporting Infor-
mationTable S2). A 1-week downward titration for safety
reasons was also planned. The choice to test 16 mg daily,
the highest dose used in hypertension, was made on the
basis of the prazosin alcohol trial (Simpson et al. 2009),
where: (1) prazosin was used at the highest dose for
hypertension (16 mg/day); and (2) participants had a
statistically significant reduction in alcohol consumption
during the last 3 weeks, when prazosin was administered
at the full dose. Studymedication adherence was assessed
by self-report and pill count. Additionally, capsules con-
tained 25 mg riboflavin as a marker of adherence
through urine sample (Del Boca et al. 1996).
Medical management
At each medication visit, participants also received a
medical management session.Medical management is an
intervention with demonstrated efficacy as a behavioral
platform for the treatment of AD (Anton et al. 2006). The
medical management sessions provide personalized edu-
cation regarding alcohol. It is structured to help the par-
ticipant develop and implement a plan to stop/reduce
drinking, motivate participants for medication adherence
and assess AEs and concomitant medication use. The
medical management approach was based on the
COMBINE study (Anton et al. 2006) and revised and
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adapted for this study. For example, special emphasis in
the assessment of AEs was given to side effects already
described for doxazosin; particular attention was given
not only to medication adherence per se but also to the
compliance to the study medication titration during the
first 4 weeks of the trial. Special attention was given to
those concomitant medications with known possible
interaction with doxazosin.
Study procedures
The study consisted of four phases: telephone pre-
screening, in-person screening, 10-week treatment and
2-week follow-up. Potential participants, recruited via
advertisements in public transportation and mass media,
and referrals from other clinics were phone screened.
Those meeting initial pre-screening criteria came for an
in-person screen inwhich they providedwritten informed
consent. Screening (week 00 visit) included psychological
assessments,medical history, physical, electrocardiogram
and blood/urine laboratories (e.g. liver and kidney func-
tion tests, complete blood count, urine drug and preg-
nancy tests). Breathalcohol concentrationwasmeasured,
vital signs were taken and recent alcohol consumption
was collected using the timeline follow-back (TLFB; Sobell
et al. 1988).Atweek01visit (day01), eligibleparticipants
were randomized to doxazosin or placebo. A brief tel-
ephoneassessment occurred at days2–4 to assess possible
AEs. Then, participants were assessed in person at weeks
2, 3, 4, 6, 8 and 10 for in-person visits, during which
medical assessments, questionnaires, study medication
and medical management sessions were provided. A brief
telephone assessment occurred at weeks 5, 7 and 9 to
address possible AEs. At Week 10, a downward titration
dose of doxazosin/placebo was administered. Subse-
quently, 2 weeks after week 10 (thus, ∼ 1 week after the
last study medication dose), a brief in-person follow-up
visit took place to assess general health status.
Study outcomes and assessments
Drinking outcomes
Primary outcomes were DPW and heavy drinking days
(HDD) per week, as assessed by the TLFB.
Craving, anxiety and stress
It has been suggested that the role of prazosin in ADmay
be mediated by its effects on stress-related anxiety
(Walker et al. 2008; Rasmussen et al. 2009; Simpson
et al. 2009), therefore secondary outcomes were stress,
anxiety and craving. Alcohol craving was assessed by the
obsessive compulsive drinking scale (OCDS), including
the total, obsessive (ODS) and compulsive (CDS) scores
(Anton, Moak & Latham 1995). Anxiety and stress were
assessed using the Hamilton anxiety scale (HAMA)
(Hamilton 1959), the perceived stress scale (PSS; Cohen,
Kamarck & Mermelstein 1983) and the anxiety-tension
subscale of the profile of mood states (POMS-TA) (Pollock
et al. 1979).
Moderators
Analyses of family history of alcoholism, severity of AD
and gender as potential moderators of amedication effect
were planned a priori. Consistent with the literature
(Trzaskowska et al. 1986; Koob 2008; Walker et al.
2008), α1-blockade represents a mechanism of action
more likely to be effective in patients with more biologi-
cally based AD and/or higher severity of dependence. For
example, prazosin’s ability to reduce ethanol self-
administration was more potent in ethanol-dependent
rats than in non-dependent rats (Walker et al. 2008).
Consistent with previous reports (Rohsenow et al. 2007;
Capone et al. 2011), we used the family tree question-
naire (Mann et al. 1985) to calculate the family history
density of alcoholism (FHDA) among first-degree rela-
tives; FHDA was dichotomized at 0.50 (median split) into
low or high FHDA. We used the alcohol dependence scale
(ADS) (Skinner & Allen 1982) as a direct measure of
severity of dependence; ADS was dichotomized into low
or high ADS based on the median of 10.5. Finally, we
assessed gender as it has been associated with severity of
AD (Rohsenow et al. 2007).
AEs
AEwere assessed at each visit using the SAFTEE (Levine &
Schooler 1986), revised and adapted for this study. Clini-
cal assessments [e.g. blood pressure (BP)] were used to
identify other AEs.
Statistical analysis
Distributional characteristics of outcome measures were
examined to evaluate similarity to the normal distribu-
tion. DPW had a skewness and kurtosis slightly in excess
of two; consequently, the data were transformed using a
square root transformation. The mixed model procedure,
which accommodates cases with missing data, was used
to assess medication effects on outcomes with time nested
under subjects. The baseline value of each particular
dependent measure was added as a covariate. Addition-
ally, as the two groups differed in racial make-up
(Table 1), race was added as a covariate to ensure that
any differences on outcome variables between groups
were not accounted for by race difference. Chi-squared
tests were conducted to assess if demographic character-
istics, medication adherence or AEs differed between
doxazosin and placebo groups. Moderator analyses for
FHDA and ADS were conducted using a median split
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[consistent with (Rhemtulla, Brosseau-Liard & Savalei
2012), who confirmed the conventional wisdom that,
with just two to four categories, continuous methodology
is generally not recommended] while gender was already
a dichotomous variable. Consistent with recent recom-
mendations (Falk et al. 2010), the previous data showing
a prazosin effect at the target dose (Simpson et al. 2009)
and the doxazosin titration scheduled (Supporting Infor-
mationTable S2), a grace periodwas applied for the first 4
weeks of medication to account for titration to peak phar-
macological effect; therefore, except for the baseline com-
parisons, medication adherence and AE analyses, all
other analyses were conducted for the target dose
(16 mg) period only. Standard errors were reported for
mixed model analyses; standard deviations were reported
for t-tests. All participants with at least one valid outcome
data point were included in the modified intention-to-
treat analysis. SPSS version 21 (IBM Corp., Armonk, NY,
USA) was used to conduct the analyses.
RESULTS
Participant characteristics
Of 197 individuals pre-screened by phone, 52 signed the
informed consent and were screened in-person; 11 were
ineligible, while 41 were eligible and randomized
(doxazosin, n = 20: placebo, n = 21). Thirty participants
(doxazosin = 15) completed the treatment phase and 28
(doxazosin = 14) completed the follow-up (Supporting
Information Fig. S1). Participants’ baseline characteris-
tics are shown in Table 1.
Drinking outcomes
There were no significant differences between groups in
DPW (F1,36 = 0.43, P > 0.05) and HDD (F1,35 = 1.03,
P > 0.05), although there was a small reduction in DPW
and HDD in the doxazosin group compared with placebo
(effect sizes d = 0.23 and 0.35, respectively). There was
no significant time or medication by time interaction for
either of the two outcomes (Ps > 0.05). (See Supporting
InformationTable S5 for results for all terms in the model
for these two dependent variables.)
Craving, anxiety and stress
There was a significant main effect for medication on the
ODS subscale (F1,33 = 4.92, P = 0.034; Fig. 1). There
were no significant medication effects on total OCDS
(F1,35 = 2.55, P > 0.05), CDS (F1,36 = 0.87, P > 0.05),
HAMA (F1,36 = 0.46, P > 0.05), PSS (F1,36 = 0.46,
P > 0.05) or POMS-TA (F1,34 = 0.34, P > 0.05) scales.
There were no significant main effects for time or medi-
cation by time interaction for these outcomes (Ps > 0.05).
Table 1 Participant characteristics at baseline [mean ± (standard deviation) or percentage (%)].
Doxazosin
(n = 20)
Placebo
(n = 21)
Age 42.1 (10.2) 42.1 (7.5)
Women (%) 30 29
Hispanic/Latino (%) 10 5
Race (%):
American/Alaskan Indian 0 5
African–American 25 43
Whitea 65 33
Other 0 5
More than one race 10 14
Drinking per week 69.0 (33.1) 75.6 (71.2)
Heavy drinking days 5.3 (1.6) 5.1 (1.8)
Obsessive compulsive drinking scale score 18.3 (6.4) 14.8 (7.6)
Obsessive drinking scale subscore 7.7 (3.7) 6.0 (4.5)
Compulsive drinking scale subscore 10.6 (3.2) 8.9 (3.7)
Family history density of alcoholism (%) 52 38
Cigarette smokers (%) 70 71
Urine drug screen positive for cannabis (%) 10 29
Systolic blood pressure supine 126 (21) 124 (11)
Diastolic blood pressure supine 81 (13) 79 (10)
Systolic blood pressure standing 124 (16) 124 (12)
Diastolic blood pressure standing 83 (13) 83 (9)
Systolic blood pressure (BP)Δ 2.5 (12.9) −0.3 (12.1)
aχ2 [(1, n = 41) = 4.11, P = 0.04]; no other significant baseline differences between groups were found [Ps > 0.05].
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(See Supporting Information Tables S6 and S7 for results
for all terms in the model for these dependent variables.)
Moderators
Analyses for the three potential moderators (FHDA, ADS
and gender) of the two primary drinking outcomes were
conducted using an alpha corrected by a factor of
6 (3 × 2).
There were main effects of FHDA on DPW
(F1,35 = 9.48, pcorrected = 0.024) and HDD (F1,34 = 13.38,
pcorrected = 0.005), aswell as significant FHDA × medication
interactions for bothDPW(F1,35 = 17.35, pcorrected = 0.001)
and HDD (F1,34 = 25.29, pcorrected = 0.00009). Post hoc
analyses showed a significant medication effect for high
FHDA in the expected direction (i.e. reduction of drinking)
for DPW (t31 = 3.47, pcorrected = 0.003; Fig. 2a) and HDD
(t31 = 3.84, pcorrected = 0.0004; Fig. 2b). Large effect sizes
were reported for both DPW (d = 1.18) and HDD
(d = 1.30) with high FHDA as moderator (Table 2).
Notably, there was a significant reverse medication effect
for low FHDA on DPW (t29 = 2.59, pcorrected = 0.04; Fig. 2a)
Week
O
D
S 
su
bs
ca
le
6 8 10
0
2
4
6
8 * Placebo
Doxazosin
* < 0.05
Figure 1 Significant effect for doxazosin
on the obsessive craving (ODS) subscale
H
D
D
high FHDA low FHDA
0
1
2
3
4
5
Placebo
Doxazosin
D
PW
high FHDA low FHDA
0
2
4
6
8
Placebo
Doxazosin
**
***
*
   * < 0.05
  ** < 0.01
*** ≤ 0.001
***
***(a)
(b)
Figure 2 (a) Significant effect for
doxazosin on drinks per week (DPW),
family history density for alcoholism
(FHDA) × medication interaction; (b) sig-
nificant effect for doxazosin on heavy
drinking days (HDD) per week,
FHDA × medication interaction. Horizontal
lines indicate significant interactions and
brackets indicate post hoc analyses with sig-
nificant findings
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and trend for a reverse medication effect for low FHDA on
HDD (t29 = 2.40, pcorrected = 0.08; Fig. 2b). FHDA was not
related to differences in age, gender, race, ethnicity or
baselineDPWorHDD.Therewereno significant effects for
ADS or gender on the two main outcomes (data not
shown).
Exploratory analyses
Based on the earlier results for FHDA, additional analyses
wereperformed to investigate the extent towhicheffects in
secondary outcomeswere alsomoderated by FHDA.Given
the exploratory nature of these analyses, results are pre-
sentedwithuncorrectedalpha levels (Table 3).Therewere
significant main effects of FHDA on craving scales
(total OCDS: F1,34 = 6.25, P = 0.017; ODS: F1,35 = 6.97,
P = 0.012; CDSF1,34 = 5.45,P = 0.026), anxiety (HAMA:
F1,34 = 5.13, P = 0.030) and mood (POMS-TA:
F1,32 = 7.44 P = 0.010), but not PSS (P > 0.05). There
were significant FHDA by medication interactions for
craving (total OCDS: F1,35 = 10.06, P = 0.003; ODS:
F1,35 = 5.23, P = 0.028; CDS: F1,35 = 11.08, P = 0.002)
and anxiety (HAMA: F1,32 = 9.76, P = 0.004).
Study medication adherence
Percentages of days of medication adherence were as
follows: doxazosin = 85.7 (24.0) percent-days adherent
and placebo = 75.6 (32.7) percent-days adherent,
(t39 = 1.13, P = 0.27). The two groups did not differ on
medication adherence (P > 0.05).
Drug titration
There were no statistical differences between doxazosin
and placebo groups during the drug titration phase and
maximum tolerable dose. Of the 28 who completed the
study, 24 participants reached 16 mg (12 doxazosin; 12
placebo), and four completed the study at a lower dose
(maximum tolerable dose of doxazosin: one remained at
4 mg and one reached 16 mg for a week then returned to
8 mg; maximum tolerable dose of placebo: one remained
at 4 mg and one at 2 mg). Of the 13who did not complete
the study, six participants reached 16 mg (three received
doxazosin; three received placebo) and seven never
reached 16 mg (three received doxazosin, however, one
completed the 10-week study at 4 mg but did not return
for follow-up; four received placebo).
AEs
Four AEs were more frequent in the doxazosin group
versus placebo: dizziness, depression or other mood dis-
turbance, trouble urinating (Ps < 0.05) and headache
(P < 0.01; Supporting Information Table S3). Particular
attentionwas also given to BP, given doxazosin’s expected
hypotensive effects, assessed as systolic and diastolic BP
changes (BPΔ; average supine minus average standing
reading). No baseline differences were observed between
the two groups (Table 1). No significant differences in
BPΔ were observed between the two groups during treat-
ment (Supporting Information Table S4).
DISCUSSION
This study provides preliminary yet promising results on
the potential role of doxazosin in the treatment of AD.
Specifically, findings from this relative small sample do
not support a role for doxazosin in reducing alcohol use in
a general AD population; however, doxazosin may be
effective in reducing drinking and craving in AD patients
with high FHDA.While this trial was developed based only
on the previous pre-clinical and clinical literature related
to prazosin in AD, a subsequent pre-clinical study (O’Neil
et al. 2013) showed that doxazosin decreased voluntary
alcohol consumption in P rats without affecting total
fluid intake, locomotor activity or alcohol clearance. The
positive effects of doxazosin in P rats are consistent with
our clinical findings where doxazosin significantly
reduced drinking only in patients with high FHDA. In fact,
the P rat line is a well-characterized model of excessive
voluntary alcohol drinking and these lines are based on
repeated generations of selective breeding for alcohol
preference (Li et al. 1979). An additional pre-clinical
observation consistent with the present clinical findings
Table 2 Family history density of alcoholism (FHDA) as moderator of the primary drinking outcomes [mean ± (standard error)].
Drinks per week Heavy drinking days
FHDA High FHDA 4.2 (0.5) 2.3 (0.3)
Low FHDA 1.8 (0.6) 0.7 (0.4)
pcorrected 0.024 0.005
Doxazosin Placebo Doxazosin Placebo
FHDA × medication High FHDA 2.3 (0.7) 6.1 (0.8) 1.1 (0.5) 3.6 (0.5)
Low FHDA 3.3 (0.7) 0.2 (0.9) 1.7 (0.4) 0.0 (0.6)
pcorrected 0.001 0.00009
High FHDA × medication effect size (d) 1.18 1.30
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is that, in another set of experiments, prazosin was more
potent in ethanol-dependent rats than in non-dependent
rats (Walker et al. 2008).
Results also suggest that for those patients with low
FHDA, not only did doxazosin not reduce drinking, but it
also appears that there was a trend toward increased
drinking. This is interesting because it further supports
the potential selectivity of doxazosin, by suggesting not
only a subtype of AD patients (with high FHDA) for whom
doxazosin could reduce drinking, but also another
subtype for whom the use of doxazosin would not be rec-
ommended (patients with low FHDA). Furthermore, the
opposite effects of high versus low FHDA in moderating
doxazosin’s effect suggest that, when pooled together, the
two effects may cancel each other out, thus the lack of
doxazosin’s effects on drinking outcomes in the whole
general sample.
It is also important to consider the potential con-
founding by the placebo effect observed in this study as
lower alcohol use was reported by placebo-treated sub-
jects with low FHDA. In the high FHDA group, placebo
clearly was not associated with reduced alcohol drink-
ing like it did in the low FHDA group, but doxazosin did.
It is possible that doxazosin’s effect was exhibited in the
high FHDA group because they expressed adequate
drinking to resolve the response, whereas drinking in
the low FHDA group was so profoundly suppressed by
the placebo effect that the interpretation was con-
founded. It could even be plausibly hypothesized that the
low FHDA group exhibited a differentially potent placebo
effect due to motivating conditions of the clinical trial,
that doxazosin treatment could have actually dimin-
ished the impact of these conditions and allowed expres-
sion of moderate drinking, perhaps through an
anxiolytic effect, a potential explanation consistent with
what is already observed in non-dependent rats where a
low dose of prazosin actually increased alcohol self-
administration (Walker et al. 2008).
Although this study does not provide definitive
answers on the potential biobehavioral mechanism(s) of
action, some hypotheses are possible. The effect of
doxazosin in reducing alcohol craving in patients with
high FHDA, in the absence of effects on anxiety and
stress, could suggest one potential pathway. Notably,
these outpatients were exposed to alcohol cues in their
‘real-word’ life and these cues might have frequently
elicited craving, against which doxazosin may have
facilitated its effect in those with high FHDA. Taking into
account the consistent doxazosin suppression of alcohol
craving reflected in the obsessive drinking score and the
potential confounding by placebo effect on alcohol con-
sumption discussed earlier, it is possible to speculate that
doxazosin treatment may be effective only in subjects
that are expressing high voluntary alcohol drinking, aTa
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potential explanation consistent with previous rodents
research showing that other drugs working on the
noradrenergic system suppress alcohol drinking in high
alcohol-drinking but not in low alcohol-drinking rats
(Moorman & Aston-Jones 2009). While drawing conclu-
sive findings in this domain is beyond the scope of
this research, human laboratory studies assessing
doxazosin’s effects on craving may be helpful to better
investigate this putative mechanism of action.
Another potential mechanism of action is via influ-
ence on stress-induced anxiety and stress-induced
relapse/reinstatement of alcohol seeking, which are
mediated, at least partially, by the norepinephrine
system (Koob 2008). However, the present study
provides no support for this putative mechanism of
action in humans. It is conceivable that an effect of
doxazosin on anxiety and/or stress could be detected in
a different study design with abstinent AD patients who
start doxazosin after an in-patient detoxification phase.
Supporting evidence for this includes the fact that brain
α1-adrenergic mechanisms mediate enhanced acoustic
startle response (Stevens et al. 1994), which is charac-
teristic of abstinent alcoholic individuals (Krystal
et al. 1997) and outbred rats experiencing prolonged
abstinence following long-term chronic daily ethanol
consumption and withdrawal (Rasmussen et al.
2009).
An open question remains with what may be the
potential causes underlying differential doxazosin
response by family history of alcoholism. We examined if
high FHDAwas a proxy of another more direct biomarker
but found that FHDA was not related to baseline differ-
ences, such as age, gender, race, ethnicity or baseline
alcohol use. One may speculate that FHDAwas a proxy of
a potential genetic biomarker that might predict
doxazosin response, an intriguing hypothesis that could
not be tested in this study, given that genetic sampling
was not conducted. Consistent with the growing litera-
ture suggesting an important role of pharmacogenetics
in AD (Heilig et al. 2011; Leggio & Schwandt 2014),
future studies will need to investigate potential biological
(genetic) markers, such as, e.g., genetic variants that
have been associated with the response to doxazosin in
hypertensive patients (Lynch et al. 2008). These objective
biomarkers might allow the identification of more precise
and replicable subtypes of AD patients more likely to
respond to doxazosin. This future line of inquiry will be
important not only because family history of alcoholism
is typically self-reported and there is not enough evidence
to suggest it as a reliable predictor of response, but also
because its implementation in clinical practice may be
challenging due to the need to standardize the way how
family history of alcoholism is defined, operationalized
and assessed.
Given recent findings suggesting a role of doxazosin in
posttraumatic stress disorder (PTSD; De Jong et al. 2010)
and cocaine abuse (Newton et al. 2012; Shorter, Lindsay
& Kosten 2013), future research exploring the role of
doxazosin in the common co-morbidities betweenAD and
both PTSD and cocaine use is worth considering. In this
regard, another important consideration is thatwhile this
preliminary study aimed at testing the maximum toler-
able dose of doxazosin, i.e. up to 16 mg/day, future
studies may also be designed as dose-ranging studies,
especially considering that lower doses of doxazosin have
been used in PTSD (De Jong et al. 2010) and cocaine
abuse (Newton et al. 2012; Shorter et al. 2013).
This study provides important information on the
safety of doxazosin specifically in the context of alcohol
misuse. While this was not a medication–alcohol interac-
tion study in a controlled in-patient setting, these findings
support the safety of doxazosin–alcohol interaction in a
‘real-word’ clinical outpatient setting.This study also pre-
sents questions on safety- and efficacy-related differences
between doxazosin and prazosin in AD. Within the
general safety profile of this class of drugs, doxazosin has
been designated as a safer medication compared with
prazosin (Akduman & Crawford 2001). The slower onset
of action of doxazosin and its relatively long t1/2 decreases
the likelihood of first-dose postural hypotension com-
pared with prazosin (Kirby et al. 1998). In the context of
AD patients, Simpson et al. (2009) reported one case of
clinically significant hypotension out of 24 enrolled
patients, while in our study (n = 41), no patients pre-
sented with clinically relevant hypotension. This is also
consistent with the observation that, while effective for
lowering BP in hypertensive patients, doxazosin has no
significant effect on BP in normotensive patients, thus
further decreasing the risk of hypotension (Akduman &
Crawford 2001). In summary, the lack of severe AEs or
other safety concerns, together with the low number of
dropouts (whose rates were similar in the doxazosin and
placebo groups), indicate that safety and tolerability of
doxazosin in this trial was fair and make it an acceptable
medication for AD patients.
In terms of efficacy, in contrast to the prazosin study
(Simpson et al. 2009), we did not find a main doxazosin
effect in the general sample. One possible explanation for
this inconsistency is that the prazosin trial overesti-
mated the medication’s effect, a potential type I error in
small RCTs. Another possibility is that, unlike prazosin,
doxazosin only works in patients with significant family
history for alcoholism. However, it is unknown if
prazosin’s effects might be even stronger in patients with
high FHDA. Only a three-arm RCT (doxazosin versus
prazosin versus placebo) would be able to address
safety- and efficacy-related differences between the two
medications.
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Although we did not collect central spinal fluid to
measure doxazosin concentrations, there is evidence
that doxazosin crosses the blood–brain barrier. Pre-
clinical studies demonstrate central nervous system
(CNS) actions of doxazosin administered peripherally
(McLeod & Cairncross 1995). In humans, somnolence is
a dose-dependent side effect of doxazosin and a pilot
study reported that doxazosin reduced PTSD symptoms
(De Jong et al. 2010). In our trial, three of the four side
effects more common in the doxazosin group were CNS-
related (dizziness, headache and mood disturbances),
further supporting doxazosin’s central effects. This is
consistent with the fact that doxazosin works on all sub-
types, α1A, α1B and α1D (Gross et al. 1989). Blockade of
the α1B subtypes (located in the brain) by doxazosin con-
tributes to the central side effects thus demonstrating
indirectly its actions in the CNS (Akduman & Crawford
2001).
Strengths of this study include that this is the first
clinical study of the efficacy of doxazosin in AD and the
enrollment of outpatient treatment-seeking AD patients,
a population more closely representing the ‘real-word’ in
terms of clinical practice. Limitations include the lack of
actual genetic testing, for which future pharmacogenetic
work is warranted; the use of riboflavin and ultraviolet
light for adherence measurement (Herron et al. 2013),
thus highlighting the need for better ways to assess
adherence in future studies (for review, see Gurvich,
Kenna & Leggio 2013) and the small sample. Notably,
although the small sample did not allow for describing
family history of alcoholism as a tripartite categorization
(Rohsenow et al. 2007), we calculated family history
based on first-degree relatives, an approach consistent
with the COMBINE study (the largest pharmacotherapy
RCT in the alcoholism field) (Anton et al. 2006) and took
into account the ‘density’ of family history, consistent
with previous recommendations (Rohsenow et al. 2007;
Capone et al. 2011).
Importantly, this initial clinical study provides a plat-
form for future studies both in terms of safety and power
estimation for efficacy and suggests that a follow-up RCT
may be designed by a priori enrollment of AD patients
with high FHDA. Considering an RCT with 80 percent
power to detect an effect size on DPW and HDD, 20 par-
ticipants with high FHDA per cell would need to be
retained. On the other hand, if participants were not
screened on FHDA, > 400 participants per cell would
need to be retained.
In conclusion, this RCT provides preliminary evidence
for a role of doxazosin in the treatment of AD, albeit
limited to patients with high FHDA. Future studies are
warranted to identify possible biomarkers of doxazosin’s
response in AD patients in order to best identify potential
AD patients who are responders or non-responders.
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